Triple negative breast cancer: a brief review of its characteristics and treatment options.
about
Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast CancerChemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 PathwaysΓ-secretase components as predictors of breast cancer outcomeVitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell linesNrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxiaCharacterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumorsDevelopment of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.Ethnic and geographic variations in corpus uteri cancer burden: evidence based on data from 29 states and the District of Columbia. CI5 IX, X and SEER data (1998-2010).Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line modelsInvolvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis.An in vitro-in vivo model of epithelial mesenchymal transition in triple negative breast cancer.GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation.IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression.FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatmentOncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer.A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.3'UTR shortening and EGF signaling: implications for breast cancer.Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity.Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer.QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells.The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.Integrative network-based approach identifies central genetic and transcriptomic elements in triple-negative breast cancer.
P2860
Q26801886-8CBEF7A6-0C15-4E77-8259-928BFA7568B4Q27315022-7A0DD3A5-B931-46AC-89F3-2190CFD1771FQ28534781-926602BB-5A65-4CD2-B8AC-96D3E7CE7BE3Q28542814-66A44BDB-5545-40B2-9640-328508BF7A57Q28828596-F1937E22-FA46-4355-83E1-DB407F42B761Q33796945-CE29057A-4CC0-47C9-A063-CEDDBB9B7EAAQ34026441-078A92FF-27E4-4A77-9B2A-5ECC0B140F6BQ34144598-C449BD56-A3BD-40F5-8B68-0B7E21D8F046Q34530885-010D2A18-8C56-49CA-A732-7795133248C8Q34739677-DFB64F6E-5093-4901-88F4-840BDE66E9CAQ34769614-F76F310B-FD3C-4361-A752-5038AEF9B5BDQ35200540-654A6128-657B-411D-9EBE-CD8AD048658AQ36171262-7A14FB83-51F1-41CF-B107-2311B49BEFB0Q36186386-37C2ED69-0CD2-43C3-B7B0-583458DB58CCQ36413261-316698AE-EFCF-41DD-A49B-B403BC82773EQ36413546-3447B9A3-A58F-40F4-84AC-024D4F42502DQ36589909-04AAB376-AC3B-4FFE-9C7E-ABC966F95A7CQ36756685-950A9F1A-034A-4B25-9228-B43A50B85970Q36771302-DB7F437E-85D2-46B0-9400-C4F2A3DCFB28Q36812342-67613C4D-CF59-4634-A7CF-831278283DF8Q37086095-96230247-04B2-4BB0-A938-106A81F010FDQ37408773-C5F8CB3F-A073-4887-B68A-CCDA9785B5BCQ37586895-9B1314AE-C374-47B0-8488-FC38472FC4B0Q38414507-126A6D26-E73C-484D-BD4E-74A11E83F12EQ38778712-CEC5D0D7-5397-49E9-B055-4FEB0BF5BBE9Q38833441-F3854F52-C134-4968-B35E-F02E73703E41Q39382063-8DE48A3C-31BA-40BF-A4C5-783ADD508075Q41078694-36C31A0C-0E3E-462F-96EF-475893181132Q41253382-B53A7E09-968A-4CBD-9801-099D48D29FC6Q44076458-66A77876-86E1-484C-BFA7-7E221C62CB6AQ44185433-90B5FE12-1B5F-4536-ABBA-0BD254BF514AQ46388405-2A5FA679-716C-4902-B010-CBF6BCB614C6Q46889307-E5733A7A-2A6C-419D-A882-AC0C0A34B7F9Q47095189-D9C403DB-6737-4BF0-9814-B788F1B77219Q47138270-AACE8CD5-97B2-4729-BEC8-0C53C64E6E9DQ47215852-F1825634-EBBA-4099-BF59-C98D8A457405Q47243874-31CDEB67-DF18-43D4-92B5-0D3DF20FF70BQ48093281-1B37C630-3C70-4564-8834-AF6D6FDBA3B4Q50855417-35035C6B-2DC9-4B52-A64A-40A6615FA5B6Q52407848-F396F031-193F-41C2-8247-60E9862BD49B
P2860
Triple negative breast cancer: a brief review of its characteristics and treatment options.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Triple negative breast cancer: ...... ristics and treatment options.
@en
type
label
Triple negative breast cancer: ...... ristics and treatment options.
@en
prefLabel
Triple negative breast cancer: ...... ristics and treatment options.
@en
P2860
P356
P1476
Triple negative breast cancer: ...... ristics and treatment options.
@en
P2093
Carrie L Griffiths
Jacqueline L Olin
P2860
P304
P356
10.1177/0897190012442062
P577
2012-05-02T00:00:00Z